The FDA has approved Fluad (MF59 adjuvanted seasonal influenza vaccine), from NVS Influenza Vaccines, the first seasonal influenza vaccine containing...
Seqirus announced results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed Fluad...
Seqirus, a global leader in influenza prevention, announced that its adjuvanted quadrivalent influenza vaccine (aQIV) - launching as Fluad Tetra - has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending the approval of the marketing authorisation application (MAA) for use in people aged 65 years and above.
Prophylaxis of influenza in the elderly (65 years of age and older). Fluad Tetra should be used in accordance with official recommendations.
Seqirus has announced results from three analyses of a total of 42 clinical trials that evaluated the safety and immunogenicity...
Active immunisation against influenza in the elderly (65 years of age and over), especially for those with an increased risk of associated complications. The use of Fluad should be based on official recommendations.
Novartis announced it has entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for...
Prophylaxis of influenza in the elderly (65 years of age and older). Adjuvanted Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus suspension for injection in pre-filled syringe Influenza vaccine, Adjuvanted with MF59C.1 should be used in accordance with official recommendations.